As we identified BTK as a downstream target of FcγRIIb signaling in murine CML cells, we proceeded to study BTK phosphorylation in Bcr-Abl-positive K562 cells upon TKI treatment. The gene discussed is BTK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.